Phase 4 N=18 Wellbutrin XL for Dysthymic Disorder
Dysthymic Disorder
Primary: Hamilton Depression Rating Scale, 24 Items (HDRS) — 14.4; 13.3 units on a scale — p=<.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=34 Escitalopram in the Treatment of Dysthymic Disorder, Double Blind
Dysthymic Disorder
Primary: Hamilton-Depression Rating Scale (HDRS-24 Items) — 10.88; 16.41 units on a scale — p=0.10
Phase 4 N=30 Duloxetine Treatment in Elderly With Dysthymia
Depression · Dysthymic Disorder
Primary: Change in Hamilton Rating Scale for Depression (HAM-D, 24-item) From 0 Weeks to 12 Weeks. — 8 units on a scale — p=<0.001
Phase 4 N=65 Duloxetine for Chronic Depression: a Double-blind Study
Dysthymic Disorder · Depressive Disorder NOS
Primary: Hamilton Depression Rating Scale (HDRS) - 24 Total Score — 5; 10 Scores on a scale — p=.003
N/A N=129 Cognitive Behavioral Therapy (REBT/CBT) Evaluation for Dysthymia in the Practice of Clinical Social Work at Primary Care
Depression · Dysthymia · Ambulatory Health Services
Primary: Change From Baseline in Severity of Depression, Measured According to the Beck Depression Inventory, at 4 and 12 Months. — 16.18; 19.90; 16.29; 20.90 score on a scale
Phase 4 N=59 Desvenlafaxine vs. Placebo Treatment of Chronic Depression
Dysthymic Disorder · Dysthymia · Chronic Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HDRS24) — 14.63; 14.21 units on a scale — p=0.09
Phase 2 N=97 Assessing Symptomatic Clinical Episodes in Depression
Major Depressive Disorder
Primary: MADRS Score - Overall Change From Baseline — 13.7; 8.8 score on a scale — p=<.001
N/A N=205 Depression Attention for Women Now (The DAWN Study)
Depressive Disorder
Primary: Depression Treatment Outcome — 0.96; 1.33 units on a scale
Phase 3 N=292 Functional Dyspepsia Treatment Trial
Dyspepsia and Other Specified Disorders of Function of Stomach
Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05
Phase 4 N=86 Maintenance Treatment of Bipolar Depression
Bipolar Disorder · Depression
Primary: Mania Rating Scale — 4.54; 5.57 units on a scale
N/A N=44 Transcranial Direct Current Stimulation Therapy for Bipolar Depression
Depression, Bipolar · Bipolar Disorder · Mood Disorders
Primary: Number of Participants With Clinical Response [ Time Frame: At 6 Weeks Following Course of tDCS Treatment ] — 34 Participants
Phase 4 N=22 Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome
Major Depressive Disorder · Soft Tissue Discomfort Syndrome · Pain
Primary: 24-hour Activity Level
Phase 3 N=48 Major Depressive Disorder With Mixed Features - Extension
Major Depressive Disorder
Primary: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) — 66.7 percentage of subjects
Phase 3 N=463 A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint — -23.9; -21.6 units on a scale — p=0.193
Phase 3 N=337 A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint — -24.3; -23.7; -24.3 units on a scale — p=0.999
Phase 4 N=480 Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Total Discontinuation - Emergent Signs and Symptoms (DESS) Score Over the First 2 Weeks of the Double-blind Phase — 4.1; 4.8; 5.3 scores on a scale
Phase 2 N=25 Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression
Panic Disorder · Major Depressive Disorder
Primary: Panic Disorder Severity Scale (PDSS) — 6; 1 responders
Phase 3 N=569 A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Depressive Disorder, Major
Primary: Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8/Withdrawal — -13.9; -14.4; -12.9 Scores on a scale — p=0.853
Phase 2 N=204 Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
Major Depressive Disorder
Primary: Change From Baseline in Hamilton Depression Rating Scale (HAMD-17) Total Score at Weeks 8 — -9.0; -7.4 Scores on a scale — p=0.121
Phase 3 N=363 A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Major Depressive Disorder
Primary: Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score (n=102, 104, 106) — -22.85; -23.70; -24.37 Score on a scale…
Phase 3 N=211 Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Major Depressive Disorder With Mixed Features
Primary: Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores — -20.5; -13.0 units on a scale — p=<0.0001
N/A N=77 Role of Slow-wave Activity and Plasticity in MDD
Depression
Primary: Compare Indices of Net Synaptic Strength (Transcranial Magnetic Stimulation Evoked Potentials) in Individuals With MDD to Healthy Controls — 195.07; 179.16; 323.22…
Phase 3 N=340 A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Major Depressive Disorder
Primary: Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score — -23.07; -24.79; -22.61 Score on a Scale — p=0.226
Phase 2 N=12 Treatment of Depersonalization Disorder With Transcranial Magnetic Stimulation (TMS)
Depersonalization Disorder
Primary: Cambridge Depersonalization Scale (CDS) — 6 responders (>50% reduction in CDS score)
Phase 2 N=53 A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation
Mood Disorder · Mental Disorder Diagnosed in Childhood · Attention Deficit and Disruptive Behavior Disorder
Primary: Percentage of Participants That "Much Improved" (Score of 2) in, or "Completely Recovered" (Score of 1) From Their Irritability Severity, as Measured With the Clinical…
N/A N=128 Cognitive Therapy for Unipolar Depression: Efficacy of a Dilemma-Focused Intervention
Major Depressive Disorder · Dysthymic Disorder
Primary: Change From Baseline in Beck Depression Inventory-Second Edition (BDI-II) at the End of Therapy, 3 and 12-month Follow-up — 37.23; 36.94; -17.62; -15.52 units on a scale…
N/A N=100 Supportive and Supportive-Expressive Treatment for Depression
Major Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HRSD) — 12.32; 12.06; 20.20; 20.08 units on a scale — p=.016
Early Phase 1 N=28 D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
Body Dysmorphic Disorder
Primary: Body Dysmorphic Disorder Yale-Brown Obsessive Compulsive Scale (BDD-YBOCS) — 19.64; 18.77 units on a scale
Phase 4 N=483 A Study of Patients With Major Depressive Disorder and Residual Apathy
Major Depressive Disorder
Primary: Change From Baseline in the Apathy Evaluation Scale - Clinician Rated Version (AES-C) Total Score at Week 8 — -13.88; -13.50 units on a scale — p=0.612
N/A N=1,385 Sleep to Prevent Evolving Affecting Disorders
Insomnia, Primary · Depression
Primary: Severity of Depression as Measured by the Quick Inventory of Depressive Symptomatology (QIDS) Pre-Treatment — 10.8; 10.8 score on a scale